120 related articles for article (PubMed ID: 12941341)
1. Potent quinoxaline-based inhibitors of PDGF receptor tyrosine kinase activity. Part 1: SAR exploration and effective bioisosteric replacement of a phenyl substituent.
Myers MR; He W; Hanney B; Setzer N; Maguire MP; Zulli A; Bilder G; Galzcinski H; Amin D; Needle S; Spada AP
Bioorg Med Chem Lett; 2003 Sep; 13(18):3091-5. PubMed ID: 12941341
[TBL] [Abstract][Full Text] [Related]
2. Potent quinoxaline-based inhibitors of PDGF receptor tyrosine kinase activity. Part 2: the synthesis and biological activities of RPR127963 an orally bioavailable inhibitor.
He W; Myers MR; Hanney B; Spada AP; Bilder G; Galzcinski H; Amin D; Needle S; Page K; Jayyosi Z; Perrone MH
Bioorg Med Chem Lett; 2003 Sep; 13(18):3097-100. PubMed ID: 12941342
[TBL] [Abstract][Full Text] [Related]
3. PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine.
Banai S; Wolf Y; Golomb G; Pearle A; Waltenberger J; Fishbein I; Schneider A; Gazit A; Perez L; Huber R; Lazarovichi G; Rabinovich L; Levitzki A; Gertz SD
Circulation; 1998 May; 97(19):1960-9. PubMed ID: 9609090
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships for 5-substituted 1-phenylbenzimidazoles as selective inhibitors of the platelet-derived growth factor receptor.
Palmer BD; Kraker AJ; Hartl BG; Panopoulos AD; Panek RL; Batley BL; Lu GH; Trumpp-Kallmeyer S; Showalter HD; Denny WA
J Med Chem; 1999 Jul; 42(13):2373-82. PubMed ID: 10395478
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors.
Boschelli DH; Wu Z; Klutchko SR; Showalter HD; Hamby JM; Lu GH; Major TC; Dahring TK; Batley B; Panek RL; Keiser J; Hartl BG; Kraker AJ; Klohs WD; Roberts BJ; Patmore S; Elliott WL; Steinkampf R; Bradford LA; Hallak H; Doherty AM
J Med Chem; 1998 Oct; 41(22):4365-77. PubMed ID: 9784112
[TBL] [Abstract][Full Text] [Related]
6. Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo.
Myllärniemi M; Frösen J; Calderón Ramirez LG; Buchdunger E; Lemström K; Häyry P
Cardiovasc Drugs Ther; 1999 Apr; 13(2):159-68. PubMed ID: 10372232
[TBL] [Abstract][Full Text] [Related]
7. A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling.
Waltenberger J; Uecker A; Kroll J; Frank H; Mayr U; Bjorge JD; Fujita D; Gazit A; Hombach V; Levitzki A; Böhmer FD
Circ Res; 1999 Jul; 85(1):12-22. PubMed ID: 10400906
[TBL] [Abstract][Full Text] [Related]
8. Stent-induced restenosis in the swine coronary artery is inhibited by a platelet-derived growth factor receptor tyrosine kinase inhibitor, TKI963.
Bilder G; Amin D; Morgan L; McVey M; Needle S; Galczenski H; Leadley R; He W; Myers M; Spada A; Luo Y; Natajaran C; Perrone M
J Cardiovasc Pharmacol; 2003 Jun; 41(6):817-29. PubMed ID: 12775958
[TBL] [Abstract][Full Text] [Related]
9. Potent platelet-derived growth factor-beta receptor (PDGF-betaR) inhibitors: Synthesis and structure-activity relationships of 7-[3-(cyclohexylmethyl)ureido]-3-{1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl}quinoxalin-2(1H)-one derivatives.
Aoki K; Obata T; Yamazaki Y; Mori Y; Hirokawa H; Koseki J; Hattori T; Niitsu K; Takeda S; Aburada M; Miyamoto K
Chem Pharm Bull (Tokyo); 2007 Feb; 55(2):255-67. PubMed ID: 17268099
[TBL] [Abstract][Full Text] [Related]
10. Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.
Schroeder MC; Hamby JM; Connolly CJ; Grohar PJ; Winters RT; Barvian MR; Moore CW; Boushelle SL; Crean SM; Kraker AJ; Driscoll DL; Vincent PW; Elliott WL; Lu GH; Batley BL; Dahring TK; Major TC; Panek RL; Doherty AM; Showalter HD
J Med Chem; 2001 Jun; 44(12):1915-26. PubMed ID: 11384237
[TBL] [Abstract][Full Text] [Related]
11. Indolocarbazoles: potent and selective inhibitors of platelet-derived growth factor receptor autophosphorylation.
Spacey GD; Uings IJ; Slater M; Hirst S; Bonser RW
Biochem Pharmacol; 1998 Feb; 55(3):261-71. PubMed ID: 9484791
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor.
Palmer BD; Smaill JB; Boyd M; Boschelli DH; Doherty AM; Hamby JM; Khatana SS; Kramer JB; Kraker AJ; Panek RL; Lu GH; Dahring TK; Winters RT; Showalter HD; Denny WA
J Med Chem; 1998 Dec; 41(27):5457-65. PubMed ID: 9876115
[TBL] [Abstract][Full Text] [Related]
13. Weekly dosing with the platelet-derived growth factor receptor tyrosine kinase inhibitor SU9518 significantly inhibits arterial stenosis.
Yamasaki Y; Miyoshi K; Oda N; Watanabe M; Miyake H; Chan J; Wang X; Sun L; Tang C; McMahon G; Lipson KE
Circ Res; 2001 Mar; 88(6):630-6. PubMed ID: 11282898
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor.
Dahring TK; Lu GH; Hamby JM; Batley BL; Kraker AJ; Panek RL
J Pharmacol Exp Ther; 1997 Jun; 281(3):1446-56. PubMed ID: 9190882
[TBL] [Abstract][Full Text] [Related]
15. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.
Panek RL; Lu GH; Klutchko SR; Batley BL; Dahring TK; Hamby JM; Hallak H; Doherty AM; Keiser JA
J Pharmacol Exp Ther; 1997 Dec; 283(3):1433-44. PubMed ID: 9400019
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and SAR of novel imidazoquinoxaline-based Lck inhibitors: improvement of cell potency.
Chen P; Iwanowicz EJ; Norris D; Gu HH; Lin J; Moquin RV; Das J; Wityak J; Spergel SH; de Fex H; Pang S; Pitt S; Shen DR; Schieven GL; Barrish JC
Bioorg Med Chem Lett; 2002 Nov; 12(21):3153-6. PubMed ID: 12372522
[TBL] [Abstract][Full Text] [Related]
17. Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A.
Bilder G; Wentz T; Leadley R; Amin D; Byan L; O'Conner B; Needle S; Galczenski H; Bostwick J; Kasiewski C; Myers M; Spada A; Merkel L; Ly C; Persons P; Page K; Perrone M; Dunwiddie C
Circulation; 1999 Jun; 99(25):3292-9. PubMed ID: 10385505
[TBL] [Abstract][Full Text] [Related]
18. Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins.
Gazit A; App H; McMahon G; Chen J; Levitzki A; Bohmer FD
J Med Chem; 1996 May; 39(11):2170-7. PubMed ID: 8667360
[TBL] [Abstract][Full Text] [Related]
19. Cudratricusxanthone A isolated from the root bark of Cudrania tricuspidata inhibits the proliferation of vascular smooth muscle cells through the suppression of PDGF-receptor beta tyrosine kinase.
Kim TJ; Han HJ; Hong SS; Hwang JH; Hwang BY; Yoo HS; Jin YR; Lee JJ; Yu JY; Lee KH; Kang BW; Yun YP
Biol Pharm Bull; 2007 Apr; 30(4):805-9. PubMed ID: 17409526
[TBL] [Abstract][Full Text] [Related]
20. Bis(1H-2-indolyl)methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase.
Mahboobi S; Teller S; Pongratz H; Hufsky H; Sellmer A; Botzki A; Uecker A; Beckers T; Baasner S; Schächtele C; Uberall F; Kassack MU; Dove S; Böhmer FD
J Med Chem; 2002 Feb; 45(5):1002-18. PubMed ID: 11855980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
